Statin based trials in subjects with coronary heart disease: trials with clinical CHD end points
| Lipid lowering (% change) | |||||
|---|---|---|---|---|---|
| Treatment (duration) | Chol | Trig | HDL | Reduction in CHD end point | |
| NS, non-significant/no change. | |||||
| Baseline mean cholesterol 5.3 –6.9 mmol/l. | |||||
| Scandinavian Simvastatin Survival Study (4S) (1994)w10 | Simvastatin (5.4 years) | −25 | −10 | +8 | ↓34%; ↓42% CHD death |
| Cholesterol and Recurrent Events (CARE) (1996)w11 | Pravastatin (5 years) | −20 | −14 | +5 | ↓24%; ↓20% CHD death |
| Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) (1998)w12 | Pravastatin (6 years) | −18 | −11 | +6 | ↓24%; ↓24% CHD death |
| Atorvastatin versus Revascularization Treatment (AVERT) (1999)w13 | Atorvastatin v angioplasty + other lipid treatment (1.5 years) | −31 | −11 | +8 | ↓36% “ischaemic events” (angioplasty, CABG, hospitalisation for angina) |
| Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) (2000)w14 | Pravastatin (6.2 years) | −18 | −11 | +4 | ↓26% |
| Fluvastatin in Acute Myocardial Infarction (FLORIDA) (2002)w15 | Fluvastatin (1 year) | −23 (LDL) | NS | ||
| Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes (MIRACL) (2001)w16 | Atorvastatin (16 weeks) | −27 | −16 | +4 | NS (only ↓re-hospitalisation for symptomatic myocardial ischaemia) |
| Heart Protection Study (HPS) (2002)w17 | Simvastatin (5 years) | −20 | −16 | +3 | ↓24% |
| Lescol Intervention Prevention Study (LIPS) (2002)w18 | Fluvastatin (3.9 years) | -27 (LDL) | −22 | +22 | ↓26% (cardiac death, MI or revascularisation) |